ESSA PHARMA INC. news, videos and press releases
For more news please use our advanced search feature.
ESSA PHARMA INC. - More news...
ESSA PHARMA INC. - More news...
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
- ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
- ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
- ESSA Pharma to Present at the JonesHealthcare Seaside Summit
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
- ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
- ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
- ESSA Pharma to Present at the Jefferies London Healthcare Conference
- ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
- ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
- Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma?
- Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma?
- ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
- Thinking about buying stock in Lithium Americas, AGNC Investment, PCTEL, ESSA Pharma, or Sigma Additive Solutions?
- ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
- ESSA Pharma Appoints Lauren Merendino to its Board of Directors
- ESSA Pharma to Present at 2023 Jefferies Healthcare Conference
- ESSA Pharma to Present at JMP Securities Life Sciences Conference
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023
